THE BASIC PRINCIPLES OF JOURNAL OF CLINICAL BREAST CANCER

Another bispecific, humanized IgG1 antibody that is certainly below investigation is zenocutuzumab (MCLA-128), which acts by using two impartial mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 functions via a ‘dock and block’ mechanism whereby 1 arm with the antibody binds HER2